Document is current
Any future updates will be listed below
-
Authors
Gregory, Victoria
Mollan, Susan P. https://orcid.org/0000-0002-6314-4437
- License Information
-
More Information
Article History
Received: 3 February 2025
Revised: 4 February 2025
Accepted: 10 February 2025
First Online: 15 February 2025
Competing interests
: VG declares no competing interests. Professor Mollan reports consultancy fees (Invex Therapeutics; Velux foundation); advisory board fees (Invex therapeutics; Gensight) and speaker fees (Heidelberg engineering; Chugai-Roche Ltd; Allergan; Santen; Chiesi; and Santhera).
Free to read: This content has been made available to all.
